DANA-FARBER CANCER INSTITUTE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1947-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.dana-farber.org/
Capecitabine For Nasopharyngeal Cancer
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 3
- Registration Number
- NCT00095901
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
Letrozole in Preventing Breast Cancer in Postmenopausal Women
- First Posted Date
- 2004-09-08
- Last Posted Date
- 2018-03-30
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 49
- Registration Number
- NCT00090857
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Chemotherapy Plus Radiation Therapy in Treating Patients With Squamous Cell Cancer of the Head and Neck
- Conditions
- Head and Neck Cancer
- Interventions
- Drug: TaxotereRadiation: Radiation therapy
- First Posted Date
- 2004-08-13
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 22
- Registration Number
- NCT00003200
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Harvard Community Health Plan, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Troglitazone in Treating Patients With Liposarcoma
- First Posted Date
- 2004-08-12
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 85
- Registration Number
- NCT00003058
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Combination Chemotherapy in Treating Patients With Stage IIB, Stage III, or Stage IV Cancer of the Nasopharynx
- Conditions
- Head and Neck Cancer
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2009-02-09
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT00004164
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
- Conditions
- Melanoma (Skin)
- Interventions
- Biological: autologous dendritic cell-tumor fusion vaccineBiological: gp100 antigenBiological: therapeutic autologous dendritic cells
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2009-02-09
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00085397
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
- Conditions
- Central Nervous System Tumor, Pediatric
- Interventions
- Biological: filgrastimDrug: cisplatinDrug: cyclophosphamideDrug: cytarabineDrug: dexrazoxane hydrochlorideDrug: doxorubicin hydrochlorideDrug: etoposideDrug: leucovorin calciumDrug: methotrexateDrug: temozolomideDrug: therapeutic hydrocortisoneDrug: vincristine sulfateRadiation: radiation therapyDrug: Dactinomycin
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT00084838
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus, Atlanta, Georgia, United States
Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer
- Conditions
- Head and Neck Cancer
- Interventions
- Biological: IL-12
- First Posted Date
- 2004-06-04
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 7
- Registration Number
- NCT00004070
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2004-05-17
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 57
- Registration Number
- NCT00083031
- Locations
- 🇺🇸
Massachusetts General Hosptial, Boston, Massachusetts, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy
- Conditions
- Graft Versus Host DiseaseLeukemiaLymphomaMyelodysplastic SyndromesMyeloma
- Interventions
- Drug: cyclophosphamideDrug: cyclosporineDrug: leucovorin calciumDrug: methotrexateDrug: methylprednisoloneProcedure: in vitro-treated bone marrow transplantationRadiation: radiation therapy
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT00005988
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Minnesota Cancer Center, Minneapolis, Minnesota, United States